Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$3.41M-$3.41MN/M vs Q3 2023 EPS Diluted-$1.53-$1.53N/M vs Q3 2023 Operating Income-$3,604,000N/M Operating Cash Flowderived-$2,737,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end